

5 March 2025

The Manager Companies  
ASX Limited  
20 Bridge Street  
Sydney NSW 2000

(2 pages by email)

Dear Madam

**COMMENCEMENT OF RIGHTS TRADING ON ASX  
ASX: BITR**

Biotron Limited (**ASX:BIT**) (Biotron or the Company) refers to rights issue announced to the ASX on 28 February 2025 and which will be made under a prospectus lodged with ASIC on 3 March 2025 (**Rights Issue**). Trading of rights for the Rights Issue have commenced trading today under the ASX ticker code **BITR**.

The Rights Issue is being offered to shareholders registered at the Record Date of 6 March 2025 with a registered address in Australia and New Zealand (Eligible Shareholders) on the basis of 1 new share (New Shares) for every 1 shares held at an offer price of \$0.003 per share.

To give Eligible Shareholders more time to receive the document that will be dispatched after the record date, the Company has agreed to extend the closing date for the Rights Issue to 25 March 2025. The timetable for the Rights Issue will now be as follows:

Record date to determine Entitlement (Record Date)	7pm AEDT 6 March 2025
Prospectus with Entitlement and Acceptance Form sent to Eligible Shareholders	10 March 2025
Offer opens for receipt of Applications	10 March 2025
Rights trading ends at close of trading	18 March 2025
Unless otherwise determined by ASX, new shares quoted on a deferred settlement basis from market open.	19 March 2025
Latest date to extend the Rights Issue	20 March 2025

Closing date for acceptances	5pm AEDT 25 March 2025
Announce results of the Rights Issue	1 April 2025
Issue of New Shares	1 April 2025
Normal trading of New Shares expected to commence	2 April 2025
Dispatch of shareholding statements	2 April 2025
Last date to issue Shortfall Shares	25 June 2025

Note: The Directors may extend the Closing Date by giving at least 3 Business Days' notice to ASX prior to the Closing Date, subject to such date being no later than 3 months after the date of the Prospectus. As such the date the New Shares are expected to commence trading on ASX may vary.

Eligible Shareholders may take up shortfall in addition to their entitlements under the Rights Issue. Applications for securities under the Rights Issue can be made via BPAY® by following the instructions set out in the personalized Entitlement and Acceptance Form that will be sent to Eligible Shareholders with the prospectus. Persons should consider the prospectus in deciding whether to acquire securities under the Rights Issue.

A supplementary prospectus for the extension has been lodged with ASIC and accompanies this announcement.

For more information please contact:


**Enquiries:**

Dr Michelle Miller  
 Managing Director  
 +61-(0) 41231 3329

Peter Nightingale  
 Company Secretary  
 +(612) 9300 3344

This announcement has been authorised for release to the market by the Managing Director.

Yours sincerely



Peter J. Nightingale  
 Company Secretary

pjn12539

**About Biotron:**

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1 and COVID-19 and promising preclinical programs for HBV and other serious viruses. In addition, Biotron has several earlier stage programs designing drugs that target a class of virus protein known as viroporins which have a key role in the virus life cycle of a very broad range of viruses, many of which have caused worldwide health issues such as Coronavirus, Dengue, Ebola, Middle East Respiratory virus, Influenza and Zika viruses.